Quarterly ResultAug 6, 2026, 04:44 PM
Corbus Q2 Net Loss $35.0M; R&D Expenses Up 105% YoY
AI Summary
Corbus Pharmaceuticals reported a net loss of $35.0 million for Q2 2026, an increase from $17.7 million in Q2 2025, primarily due to a 105% rise in research and development expenses to $31.2 million. The company maintains a strong liquidity position, expecting its $117.9 million in cash, cash equivalents, and investments to fund operations for at least 12 months. Key activities included a $10.0 million milestone payment for CRB-701 and raising $9.1 million through an at-the-market offering.
Key Highlights
- Net loss for Q2 2026 was $35.0 million, up from $17.7 million in Q2 2025.
- Research and development expenses increased 105% to $31.2 million in Q2 2026.
- Cash, cash equivalents, and investments totaled $117.9 million at June 30, 2026.
- Paid $10.0 million development milestone for CRB-701 under CSPC License Agreement.
- Sold 894,044 common shares for $9.1 million net proceeds in Q2 2026.
- Accumulated deficit reached $613.4 million as of June 30, 2026.
- Shelf registration statement for up to $300 million of securities is effective.
Price Impact
More from CRBP